Corticosteroid Therapy in IgA Nephropathy
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
The benefits and risks of steroids for the treatment of IgA nephropathy remain uncertain. We systematically searched MEDLINE, EMBASE, and the Cochrane Library for randomized, controlled trials of corticosteroid therapy for IgA nephropathy published between 1966 and March 2011. We identified nine relevant trials that included 536 patients who had urinary protein excretion >1 g/d and normal renal function. Forty-six (8.6%) of these patients developed a kidney failure event, defined as doubling of the serum creatinine/halving of the GFR or ESRD. Overall, steroid therapy was associated with a lower risk for kidney failure (relative risk, 0.32 [95% confidence interval [CI], 0.15-0.67]; P=0.002) and a reduction in proteinuria (weighted mean difference, -0.46 g/d [95% CI, -0.63 to -0.29 g/d]), with no evidence of heterogeneity in these outcomes. Subgroup analysis suggested that the dose modifies the effect of steroids for renal protection (P for heterogeneity=0.030): Relatively high-dose and short-term therapy (prednisone >30 mg/d or high-dose pulse intravenous methylprednisolone with duration ≤1 year) produced significant renal protection, whereas low-dose, long-term steroid use did not. Steroid therapy was associated with a 55% higher risk for adverse events. The quality of included studies was low, however, limiting the generalizability of the results. In conclusion, steroids appear to provide renal protection in patients with IgA nephropathy but increase the risk for adverse events. Reliably defining the efficacy and safety of steroids in IgA nephropathy requires a high-quality trial with a large sample size.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis published in 2012 suggested that there were bene fi ts resulting from the use of corticosteroid therapy, but it was noted that trials included in the meta-analysis were small and of poor quality, with adverse outcomes not fully reported. 27”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [27]
In the citing paper
“A meta-analysis published in 2012 suggested that there were bene fi ts resulting from the use of corticosteroid therapy, but it was noted that trials included in the meta-analysis were small and of poor quality, with adverse outcomes not fully reported. 27”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [27]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Commonest Glomerulonephritis in the World: IgA Nephropathy
(1987) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068143 · Cited by 870
Bias in meta-analysis detected by a simple, graphical
Stuck, A. E., Rubenstein, L. Z., Wieland, D., Vandenbroucke, J. P., Irwig, L., Macaskill, P., Berry, G., Glasziou, P., Seagroatt, V., Stratton, I., et al. (1998) · BMJ · doi:10.1136/bmj.316.7129.469 · Cited by 699
Donadio, J. V., & Grande, J. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020109 · Cited by 661
Remission of Proteinuria Improves Prognosis in IgA Nephropathy
Reich, H. N., Troyanov, S. A. A., Scholey, J. W., & Cattran, D. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050526 · Cited by 639
Corticosteroids in IgA nephropathy: a randomised controlled trial
Pozzi, C., Bolasco, P., Fogazzi, G., Andrulli, S., Altieri, P., Ponticelli, C., & Locatelli, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03563-6 · Cited by 532
Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors
D’Amico, G. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.8966 · Cited by 499
Thompson, S. G., & Pocock, S. J. (1991) · The Lancet · doi:10.1016/0140-6736(91)91975-z · Cited by 487
Cited by
Rodrigues, J. C., Haas, M., & Reich, H. N. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07420716 · Cited by 555
Lv, J., Zhang, H., Wong, M. G., Jardine, M. J., Hladunewich, M., Jha, V., Monaghan, H., Zhao, M., Barbour, S., Reich, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.9362 · Cited by 540
Self-citationLai, K. N., Tang, S. C. W., Schena, F. P., Novak, J., Tomino, Y., Fogo, A. B., & Glassock, R. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.1 · Cited by 508
“A metaanalysis of nine RCTs (including 536 patients with urinary protein excretion of >1 g per day and normal renal function) suggested that highdose, shortterm corticosteroid therapy produced significant renal protection, whereas lowdose, longterm corticosteroid use did not 93 .”
Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
“A meta-analysis published in 2012 suggested that there were benefits resulting from the use of corticosteroid therapy, but it was noted that trials included in the meta-analysis were small and of poor quality, with adverse outcomes not fully reported.(26) Since then, larger clinical trials have addressed the role of s…”
ResultFellström, B. C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J. W., Floege, J., Hetzel, G., Jardine, A. G., Locatelli, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30550-0 · Cited by 414
Tinospora cordifolia: One plant, many roles
Ghosh, S., & Saha, S. (2012) · Ancient Science of Life · doi:10.4103/0257-7941.107344 · Cited by 404
Lv, J., Wong, M. G., Hladunewich, M. A., Jha, V., Hooi, L. S., Monaghan, H., Zhao, M., Barbour, S., Jardine, M. J., Reich, H. N., et al. (2022) · JAMA · doi:10.1001/jama.2022.5368 · Cited by 354
Self-citationFloege, J., & Amann, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00272-5 · Cited by 306
New developments in the genetics, pathogenesis, and therapy of IgA nephropathy
Magistroni, R., D’Agati, V. D., Appel, G. B., & Kiryluk, K. (2015) · Kidney International · doi:10.1038/ki.2015.252 · Cited by 302
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis
Beck, L., Bomback, A. S., Choi, M. J., Holzman, L. B., Langford, C., Mariani, L. H., Somers, M. J., Trachtman, H., & Waldman, M. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.06.002 · Cited by 234
“to no improvement using longer term low-dose therapy with regard to doubling of serum creatinine, halving of the GFR, or ESRD.(114)”
MethodHou, J.-H., Le, W.-B., Chen, N., Wang, W.-M., Liu, Z.-S., Liu, D., Chen, J.-H., Tian, J., Fu, P., Hu, Z.-X., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.11.027 · Cited by 177
Self-citationInker, L. A., Mondal, H., Greene, T., Masaschi, T., Locatelli, F., Schena, F. P., Katafuchi, R., Appel, G. B., Maes, B. D., Li, P. K., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.02.042 · Cited by 160
Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy
Rauen, T., Fitzner, C., Eitner, F., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017060713 · Cited by 104
Clinical Challenges in Diagnosis and Management of Diabetic Kidney Disease
Stanton, R. C. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.050 · Cited by 115
“73 m(2) because recent research has shown that intervening with steroids in the appropriate patient may slow progression.(27) The decision to biopsy also is affected significantly by other factors, such as the likelihood of”
BackgroundGlucocorticoids in the Treatment of Glomerular Diseases: Pitfalls and Pearls
Ponticelli, C. E., & Locatelli, F. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12991117 · Cited by 110
IgA nephropathy: A brief review
Hassler, J. R. (2020) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2020.03.001 · Cited by 98
Secondary Immunodeficiency Related to Kidney Disease (SIDKD)—Definition, Unmet Need, and Mechanisms
Steiger, S., Rossaint, J., Zarbock, A., & Anders, H. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021091257 · Cited by 96
Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Heerspink, H. J. L., & van Raalte, D. H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00030-3 · Cited by 90
Tinospora cordifolia: a multipurpose medicinal plant- A review
Mittal, J., Sharma, M. M., & Batra, A. (2014) · Journal of Medicinal Plants Studies · Cited by 158
IgA Nephropathy with Minimal Change Disease
Herlitz, L., Bomback, A. S., Stokes, M. B., Radhakrishnan, J., D’Agati, V. D., & Markowitz, G. S. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11951113 · Cited by 75
Renal Manifestations of Rheumatoid Arthritis
Kapoor, T. M., & Bathon, J. M. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.06.008 · Cited by 74
The Role of TNF Superfamily Member 13 in the Progression of IgA Nephropathy
Han, S. S., Yang, S. H., Choi, M., Kim, H.-R., Kim, K., Lee, S., Moon, K. C., Kim, J. Y., Lee, H., Lee, J. P., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060677 · Cited by 62
Contemporary review of IgA nephropathy
Filippone, E. J., Gulati, R., & Farber, J. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1436923 · Cited by 72
Corticosteroids in IgA Nephropathy: Lessons from Recent Studies
Coppo, R. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060647 · Cited by 60
Leeaphorn, N., Garg, N., Khankin, E. V., Cardarelli, F., & Pavlakis, M. (2017) · Transplant International · doi:10.1111/tri.13075 · Cited by 61
Progression of IgA Nephropathy under Current Therapy Regimen in a Chinese Population
Li, X., Liu, Y., Lv, J., Shi, S., Liu, L., Chen, Y., & Zhang, H. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01990213 · Cited by 56
Self-citationInflammation in IgA nephropathy
Rauen, T., & Floege, J. (2017) · Pediatric Nephrology · doi:10.1007/s00467-017-3628-1 · Cited by 57
Tanaka, Y., Kume, S., Araki, H., Nakazawa, J., Chin‒Kanasaki, M., Araki, S., Nakagawa, F., Koya, D., Haneda, M., Maegawa, H., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.10.414 · Cited by 56
Treatment of IgA nephropathy: Recent advances and prospects
Coppo, R. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.010 · Cited by 60
Kumar, P., Kamle, M., Mahato, D. K., Bora, H., Sharma, B., Rasane, P., & Bajpai, V. K. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200430114547 · Cited by 65
Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease
Oh, G. J., Waldo, A., Paez-Cruz, F., Gipson, P. E., Pesenson, A., Selewski, D. T., Kamil, E. S., Massengill, S. F., Lafayette, R. A., Modes, M., et al. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.08.019 · Cited by 59
“observation is similar to a meta-analysis of corticosteroid therapy compared with non-immunosuppressive therapy in adult patients with IgA nephropathy, which showed that steroid therapy was associated with 55% higher risk for adverse events.(14) It is worth mentioning that many of the adverse events (e.”
ResultSarcina, C., Tinelli, C., Ferrario, F., Pani, A., Silvestri, A. D., Scaini, P., Vecchio, L. D., Alberghini, E., Buzzi, L., Baragetti, I., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02300215 · Cited by 52
Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis
Song, Y.-H., Cai, G., Xiao, Y.-F., Wang, Y., Yuan, B., Xia, Y., Wang, S., Chen, P., Liu, S., & Chen, X. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0467-z · Cited by 49
“IgAN with severe proteinuria are conventionally subjected to treatment with various immunosuppressive regimens with conflicting results [26, 27].”
BackgroundHydroxychloroquine alleviates persistent proteinuria in IgA nephropathy
Gao, R., Wu, W., Wen, Y., & Li, X. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1574-2 · Cited by 50
Novel drugs and intervention strategies for the treatment of chronic kidney disease
Heerspink, H. J. L., & de Zeeuw, D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12195 · Cited by 53
Indian herb Tinospora cordifolia and Tinospora species: Phytochemical and therapeutic application
Chaudhary, A., Das, R., Mehta, K., & Mehta, D. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31229 · Cited by 71
Kim, Y. C., Chin, H. J., Koo, H. S., & Kim, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071545 · Cited by 39
“Meta-analyses on the effectiveness of corticosteroid for IgA nephropathy showed that steroids provided renal protection but increased the risk of adverse events [15,16].”
BackgroundReily, C., Ueda, H., Huang, Z., Mestecky, J. F., Julian, B. A., Willey, C. D., & Novák, J. (2014) · Journal of Immunology Research · doi:10.1155/2014/197548 · Cited by 36
“Currently, there is no disease-specific treatment of IgAN and up to 40% of patients progress to ESRD within 20 years of diagnosis by biopsy [47, 48]; new targets for future diseasespecific treatments are needed [48].”
BackgroundKim, M. J., Schaub, S., Molyneux, K., Koller, M., Stampf, S., & Barratt, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166830 · Cited by 35
Immunoglobulin A Nephropathy: Advances in Understanding of Pathogenesis and Treatment
Lafayette, R. A., & Kelepouris, E. (2018) · American Journal of Nephrology · doi:10.1159/000481636 · Cited by 38
Hodgin, J. B., Berthier, C. C., John, R., Gröne, E., Porubský, Š., Gröne, H., Herzenberg, A. M., Scholey, J. W., Hladunewich, M., Cattran, D. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103413 · Cited by 34
“Large observational studies suggest that corticosteroids may be effective in preventing progression of IgAN [22].”
BackgroundCybulsky, A. V., Walsh, M. W., Knoll, G. A., Hladunewich, M., Bargman, J. M., Reich, H. N., Humar, A., Samuel, S. M., Bitzan, M. M., Zappitelli, M., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.12.001 · Cited by 36
Li, P., Chen, Y., Lin, H., Ni, Z., Zhan, Y., Wang, R., Yang, H., Fang, J., Wang, N., Li, W., et al. (2017) · Trials · doi:10.1186/s13063-016-1774-6 · Cited by 35
“Another clinical trial evaluating the efficacy and safety of glucocorticoids (TESTING test) is still ongoing, and our center also participated in this study [17].”
BackgroundUric Acid as a Predictor of Immunoglobulin A Nephropathy Progression: A Cohort Study of 1965 Cases
Zhu, B., Yu, D., Lv, J., Lin, Y., Li, Q., Yin, J., Du, Y., Tang, X.-L., Mao, L., Li, Q., et al. (2018) · American Journal of Nephrology · doi:10.1159/000489962 · Cited by 32
Self-citationOptimal Proteinuria Target for Renoprotection in Patients with IgA Nephropathy
Nam, K. H., Kie, J. H., Lee, M. J., Chang, T. I., Kang, E. W., Kim, D. W., Lim, B. J., Park, J. T., Kwon, Y. E., Kim, Y. L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101935 · Cited by 32
“0 g/day and preserved kidney function [18,28,29].”
Wong, M. G., Lv, J., Hladunewich, M., Jha, V., Hooi, L. S., Monaghan, H., Zhao, M., Barbour, S. J., Reich, H. N., Cattran, D. C., et al. (2021) · American Journal of Nephrology · doi:10.1159/000519812 · Cited by 37
Self-citationHematuria and risk for end-stage kidney disease
Vivante, A., Calderon‐Margalit, R., & Skorecki, K. L. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32835f7241 · Cited by 32
Chronic allograft injury: Mechanisms and potential treatment targets
Riella, L. V., Djamali, A., & Pascual, J. (2016) · Transplantation Reviews · doi:10.1016/j.trre.2016.10.005 · Cited by 40
Emerging Modes of Treatment of IgA Nephropathy
Maixnerová, D., & Tesař, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239064 · Cited by 35
“Other randomized and observational trials supported the potential effect of corticosteroids in IgAN [27,31].”
BackgroundZhou, S., Cheng, F., Zhu, L., Lv, J., Qi, Y., Hou, P., & Zhang, H. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01860213 · Cited by 30
Self-citationBarbour, S. J., Lo, C., Espino-Hernández, G., Sajjadi, S., Feehally, J., Klarenbach, S. W., & Gill, J. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx185 · Cited by 28
“Conversely, the medication costs for IgAN did not change over time, likely because steroids remain the only sufficiently studied therapy to warrant a kidney disease improving global outcomes (KDIGO) guideline recommendation for the majority of patients [1, 37].”
BackgroundTürkmen, A., Şumnu, A., Cebeci, E., Yazıcı, H., Eren, N., Seyahi, N., Dilek, K., Dede, F., Derici, Ü., Ünsal, A., et al. (2020) · BMC Nephrology · doi:10.1186/s12882-020-02134-8 · Cited by 28
Du, B., Jia, Y., Zhou, W., Xu, M., Miao, L., & Cui, W. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0647-x · Cited by 27
“Last but not least, corticosteroid recognized as the elementary medicine in treating IgAN [31] was used in only one of the five trials [12].”
BackgroundSteroid therapy in children with IgA nephropathy
Cambier, A., Boyer, O., Deschênes, G., Gleeson, P. J., Couderc, A., Hogan, J., & Robert, T. (2019) · Pediatric Nephrology · doi:10.1007/s00467-018-4189-7 · Cited by 29
Cox, S. N., Pesce, F., Moustafa, J. S. E.-S., Sallustio, F., Serino, G., Kkoufou, C., Giampetruzzi, A., Ancona, N., Falchi, M., & Schena, F. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12565 · Cited by 25
Tan, L., Tang, Y., Peng, W. J., Mathew, B. S., & Qin, W. (2018) · Kidney & Blood Pressure Research · doi:10.1159/000492592 · Cited by 26
Zhang, Z., Yang, Y., Jiang, S., & Li, W. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1519-3 · Cited by 27
Glucocorticoids for IgA nephropathy—pro
Zhang, Y., Lv, J., Wong, M. G., Zhang, H., & Perkovic, V. (2023) · Kidney International · doi:10.1016/j.kint.2023.01.018 · Cited by 26
Self-citationApproach to the Child with Hematuria
Brown, D. D., & Reidy, K. J. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.08.003 · Cited by 25
Diagnostic Tests and Treatment Options in Glomerular Disease: 2014 Update
Hogan, J. J., Mohan, P., & Appel, G. B. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.09.019 · Cited by 27
Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
Cai, Q., Xie, X., Wang, J., Shi, S., Liu, L., Chen, Y., Lv, J., & Zhang, H. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.02.003 · Cited by 21
“One meta-analysis of 9 clinical trials suggested that 6-month corticosteroid therapy could reduce the prevalence of renal failure by 68%.(13) However, these trials comprised a small number of patients, and adverse outcomes (AEs) were poorly”
BackgroundSelf-citationZhu, B., Liu, W., Yu, D., Lin, Y., Li, Q., Tong, M., Li, Y., Yang, R., Du, Y., Tang, X.-L., et al. (2020) · American Journal of Nephrology · doi:10.1159/000508770 · Cited by 20
Li, Z., Zhu, P., Huang, H., Pan, Y., Han, P., Cui, H., Kang, Z., Xun, M., Zhang, Y., Liu, S., et al. (2019) · Science China Life Sciences · doi:10.1007/s11427-018-9545-3 · Cited by 19
Treatment protocol with pulse and oral steroids for IgA Nephropathy after kidney transplantation
Messina, M., Vico, M. C. D., Ariaudo, C., Mazzucco, G., Fop, F., Segoloni, G., & Biancone, L. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0314-5 · Cited by 19
“There are several randomized controlled trials supporting the efficacy of steroids in IgAN in native kidneys [11, 12, 27, 28]; recently, Tesar et al.”
BackgroundInoue, M., Yamamotoya, T., Nakatsu, Y., Ueda, K., Inoue, Y., Matsunaga, Y., Sakoda, H., Fujishiro, M., Ono, H., Morii, K., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123967 · Cited by 20
Brent, M. B., Thomsen, J. S., & Brüel, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-91729-8 · Cited by 19
Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy
Sarcina, C., Tinelli, C., Ferrario, F., Visciano, B., Pani, A., SILVESTRI, A. D., Simone, I. D., Vecchio, L. D., Terraneo, V., Furiani, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158584 · Cited by 17
Chen, S., Yin, Q. S., Ren, S., Zhong, X., Wang, W., Li, G., & Wang, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-31727-5 · Cited by 18
Imai, K., Ishimoto, T., Doke, T., Tsuboi, T., Watanabe, Y., Katsushima, K., Suzuki, M. M., Oishi, H., Furuhashi, K., Ito, Y., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.12.011 · Cited by 16
Recent advances in the understanding and management of IgA nephropathy
Lai, K. N., Leung, J. C. K., & Tang, S. C. W. (2016) · F1000Research · doi:10.12688/f1000research.7352.1 · Cited by 16
“…nine randomized controlled trials (including 536 patients with urinary protein excretion of more than 1 g/day and normal renal function) suggested that high-dose and short-term corticosteroid therapy produced significant renal protection but that low-dose, long-term corticosteroid use did not 30 .”
BackgroundZhang, Y., Luo, J., Hu, B., & Ma, T. (2018) · Journal of International Medical Research · doi:10.1177/0300060518776566 · Cited by 16
Loss of KLF15 accelerates chronic podocyte injury
Han, S. M., Yu, M., Yoo, K., Lee, J. E., Kim, D. K., Kim, Y., & Yang, S. H. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3726 · Cited by 18
“Some of the available options, such as modulators of the renin-angiotensin-aldosterone system, do not target podocyte pathophysiology, while steroids have several side effects following prolonged use (9).”
InfluentialPrimary glomerulonephritis: A review of important recent discoveries
Floege, J. (2013) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2013.06.004 · Cited by 16
“The study concluded that corticosteroids can retard the progress of renal failure and can reduce proteinuria [34].”
BackgroundKrochmal, M., Cisek, K. K., Filip, S. K., Markoska, K., Orange, C., Zoidakis, J., Gakiopoulou, C., Spasovski, G. B., Mischak, H., Delles, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09393-w · Cited by 18
Corticosteroid for IgA Nephropathy: Are They Really Therapeutic?
Lin, Y., Jia, J., Guo, Y., He, D., Zhang, Y., Wang, F., Yan, T., Liu, Y., & Lin, S. (2018) · American Journal of Nephrology · doi:10.1159/000489580 · Cited by 18
Kim, D., Lv, J., Hladunewich, M., Jha, V., Hooi, L. S., Monaghan, H., Shan, S., Reich, H. N., Barbour, S. J., Billot, L., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.03.032 · Cited by 19
Self-citationThe road ahead: emerging therapies for primary IgA nephropathy
Filippone, E. J., Gulati, R., & Farber, J. L. (2025) · Frontiers in Nephrology · doi:10.3389/fneph.2025.1545329 · Cited by 17
“Earlier trials were of low quality and small size (61).”
Okabayashi, Y., Tsuboi, N., Haruhara, K., Kanzaki, G., Koike, K., Shimizu, A., Miyazaki, Y., Ohno, I., Kawamura, T., Ogura, M., et al. (2016) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1239-y · Cited by 18
Rasche, F. M., Keller, F., Rasche, W., Schiekofer, S., Boldt, A., Sack, U., & Fahnert, J. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12823 · Cited by 15
Enumerating the role of properdin in the pathogenesis of IgA nephropathy and its possible therapies
Ghosh, S., Das, S., Mukherjee, J., Abdullah, S., Mondal, R., Sultana, S., Sehgal, A., & Behl, T. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107429 · Cited by 16
Treatment of Progressive IgA Nephropathy: An Update
Wang, W., & Chen, N. (2013) · Contributions to nephrology · doi:10.1159/000348460 · Cited by 15
Matsushita, S., Ishikura, K., Okamoto, S., Okuda, Y., Nagaoka, Y., Harada, R., Hamada, R., Sakai, T., Hamasaki, Y., Hataya, H., et al. (2015) · Clinical and Experimental Nephrology · doi:10.1007/s10157-015-1105-3 · Cited by 15
IgA Nephropathy Factors that Predict and Accelerate Progression to End-Stage Renal Disease
Huang, L., Guo, F.-L., Zhou, J., & Zhao, Y. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9741-2 · Cited by 15
Liu, Y., Xiao, J., Shi, X., Hao, G., Chen, Q., Zhou, J., & Wei, X. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2860 · Cited by 15
The predictive value of Oxford MEST-C classification to immunosuppressive therapy of IgA nephropathy
Rui, Y., Yang, Z., Zhai, Z., Zhao, C., & Tang, L. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02974-9 · Cited by 14
An update on the treatment of IgA nephropathy
Barbour, S. J., & Feehally, J. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000336 · Cited by 14
TESTING the effects of corticosteroids in patients with IgA nephropathy
Seikrit, C., Stamellou, E., Rauen, T., & Floege, J. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac221 · Cited by 14
Efficacy and safety of glucocorticoids for patients with IgA nephropathy: a meta-analysis
Ge, Q., Zhang, X., Xu, W., Zou, H., & Li, Y. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02094-5 · Cited by 12
The Treatment of IgA Nephropathy
Lai, K. N., Leung, J. C. K., & Tang, S. C. W. (2015) · Kidney Diseases · doi:10.1159/000381508 · Cited by 11
Obrișcă, B., Sinescu, I. C., Ismail, G., & Mircescu, G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101584 · Cited by 11
Tian, L., Shao, X., Xie, Y., Wang, X., Wang, Q., Che, X., Ni, Z., & Mou, S. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1038238 · Cited by 11
“Several meta-analyses have been performed to evaluate the therapeutic value of immunosuppressive agents [11-14].”
BackgroundAl-Karawi, A. S., & Kadhim, A. S. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.111181 · Cited by 10
Efficacy and safety of finerenone in IgA nephropathy: an observational multicentre study
Wang, Q.-R., Wu, L., Huang, J., Pan, H., Wang, X.-F., Li, L., Han, F., Wang, Y., Wu, M., & Yang, Y. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf125 · Cited by 15
“While most trials focus on high-risk CKD patients with proteinuria > 1 g/day [5 , 13 ], intensive immunosuppressive therapy often causes significant side effects [6 ].”
Wang, Y., Hu, Z., Wu, J., Wang, P., Yang, Q., Li, Y., Zhu, F., Yang, J., Deng, Y., Han, M., et al. (2018) · Histopathology · doi:10.1111/his.13803 · Cited by 10
“It has been shown that inflammatory factors, including interleukin (IL)-1b and IL-4, up-regulated DC-SIGN, while dexamethasone inhibited DC-SIGN expression;(29,30) glucocorticoid therapy has been shown to be effective and safe for IgAN patients.(31,32) Glucocorticoid therapy may exercise its immunosuppressive function…”
BackgroundPeng, X., Zheng, W., Fu, R., Huang, Y.-H., Deng, M., Tao, S., Wang, T., & Zhu, C. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02028-5 · Cited by 10
Moderator's view: Treatment of IgA nephropathy—getting comfortable with uncertainty
Glassock, R. J. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw284 · Cited by 9
Sterzl, I., Hill, M., Stárka, L., Velíková, M., Kančeva, R., Jemelková, J., Czerneková, L., Kosztyu, P., Zadražil, J., Matoušovic, K., et al. (2017) · Physiological Research · doi:10.33549/physiolres.933732 · Cited by 10
Liu, Y., Xiao, J., Shi, X., Hao, G., Chen, Q., Zhou, J., & Wei, X. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7267 · Cited by 10
Rasche, F. M., Keller, F., Rasche, W., Schiekofer, S., Kahn, T., & Fahnert, J. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12719 · Cited by 11
Nagasawa, Y., Yamamoto, R., Shinzawa, M., Shoji, T., Hasuike, Y., Nagatoya, K., Yamauchi, A., Hayashi, T., Kuragano, T., Moriyama, T., et al. (2020) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01918-4 · Cited by 11
Metadata
- Authors
- Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H.
- Affiliations
- Peking University (CN)
- The University of Sydney (AU)
- The University of Queensland (AU)
- University of British Columbia (CA)
- Corresponding author
- Lv, Jicheng
- Xu, Damin
- Ma, Xinxin
- Zhang, Hong
- Wang, Haiyan
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2012-06
- Volume
- 23
- Issue
- 6
- Pages
- 1108-1116
- ISSN
- 1046-6673 (ISSN-L)
- PMC
- PMC3358763
- OpenAlex
- W2107238505
- Cited by
- 190
- References
- 33
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 12 · 2021: 13 · 2020: 13 · 2019: 13 · 2018: 16 · 2017: 24 · 2016: 22 · 2015: 16 · 2014: 13 · 2013: 13 · 2012: 2
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- IgA nephropathy, corticosteroid therapy, prednisone, methylprednisolone pulse therapy, proteinuria, renal failure, renal protection, adverse events
- MeSH terms
- Administration, Oral, Adrenal Cortex Hormones, China, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glomerulonephritis, IGA, Humans, Infusions, Intravenous, Kidney Failure, Chronic, Kidney Function Tests, Male, Methylprednisolone, Prednisone, Prognosis, Severity of Illness Index, Survival Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Disease-Free Survival, Pulse Therapy, Drug
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.